Selective Androgen Receptor Modulators Negatively Regulate Triple-Negative Breast Cancer Growth and Epithelial-Mesenchymal Stem Cell Signaling

The study demonstrated that Selective Androgen Receptor Modulators (SARMs), such as GTx-027 and GTx-024, significantly inhibited the growth and proliferation of triple-negative breast cancer (TNBC) cells both in vitro and in vivo. SARMs reduced tumor growth by over 75% and tumor weight by more than 50% without toxicity, and they also counteracted cancer-associated cachexia. SARMs suppressed key genes and pathways involved in cancer metastasis, particularly IL6 and MMP13, which are crucial for epithelial-mesenchymal stem cell interactions. These findings suggested that SARMs could be a promising therapeutic strategy for managing TNBC by targeting specific signaling mechanisms involved in cancer cell proliferation and metastasis.